EGFR and non-small cell lung carcinoma: ICIs did not improve OS vs. docetaxel in NSCLC patients with EGFR mutations (HR = 1.11 95% CI:0.80–1.53, p = 0.54) vs. WT (HR = 0.67, 95% CI:0.60–0.75, p < 0.001)